Skip to content

Concussion Pen Screening Tool

Use of the Concussion Pen in Evaluating Ocular-motor Function in the Concussed and Non-concussed Populations Ages 11 to 18 Years Old.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05432752
Enrollment
21
Registered
2022-06-27
Start date
2022-07-28
Completion date
2023-01-25
Last updated
2023-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Concussion, Fixation, Ocular

Keywords

Ocular motor function, Concussion

Brief summary

To compare the use of the Concussion Pen to current clinical care practice. This will be a prospective study of a maximum of 24 subjects, with a goal enrollment of 20 subjects (10 in each cohort). All subjects will undergo clinical evaluation for concussion and will also be evaluated using the Concussion Pen. Randomization to being evaluated using clinical care first then the Concussion Pen and vice versa will be utilized. This randomization will help to control for evaluation fatigue on the part of study participants.

Detailed description

This will be a prospective study of a maximum of 24 subjects, with a goal enrollment of 20 subjects (10 in each cohort). All subjects will undergo clinical evaluation for concussion and will also be evaluated using the Concussion Pen. All subjects (both controls and concussion patients) will undergo all eye tracking measurements. Randomization to being evaluated using clinical care first then the Concussion Pen and vice versa will be utilized. This will be a multi-disciplinary team with members of Physical Therapy (PT)/ Occupational Therapy (OT), Medical Doctor (MD), Doctor of Osteopathic Medicine (DO), and Doctor of Philosophy(PhD)s who specialize in concussion assessment. This study will include a population of concussed patients as well as non-concussed patients (controls) who will be seen in CM clinics per standard of care.

Interventions

DEVICEConcussion Pen

Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.

Sponsors

Children's Mercy Hospital Kansas City
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

All subjects will undergo clinical evaluation for concussion and will also be evaluated using the Concussion Pen. All subjects (both controls and concussion patients) will undergo all eye tracking measurements. Randomization to being evaluated using clinical care first then the Concussion Pen and vice versa will be utilized.

Eligibility

Sex/Gender
ALL
Age
11 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Inclusion Criteria for both control and study cohorts, unless stated otherwise below * Patients cognitively 11 to 18 years of age. * Patients undergoing evaluation for concussion in Children's Mercy (CM) clinics for concussion population. * Patients with a history of concussion at any previous point in time (no time limits to this date). * Patients with no history of concussion and being seen at CM PT/OT for other diagnoses for control population. * Patients able to give verbal assent or consent (dependent on patient cognitive age), and Legally Authorized Representatives (LAR)s able to give verbal parental permission. * English-speaking families.

Exclusion criteria

* Patients not within the inclusion criteria as outlined above. * Patients with congenital vestibular dysfunction will not be included. * Patients diagnosed with dyslexia or Attention Deficit Hyperactive Disorder (ADHD) will not be included. * Non-English-speaking families. * Wards of the State will not be approached for this study. * Patients with a previous diagnosis of strabismus or convergence insufficiency will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Concussion Pen versus Current Clinical Evaluation1 yearConcussion Pen is able to determine concussed patients to the same level as current clinical evaluation.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026